Abstract 1789P
Background
The volume of disease (high-volume disease (HVD) / low-volume disease (LVD)) as defined by the CHAARTED criteria based on conventional imaging, is associated with overall survival and used for treatment decisions in mHSPC patients. It remains unknown how the definition of HVD and LVD can be transferred to PSMA-PET imaging.
Methods
In this retrospective study that included 4 international sites, mHSPC patients who underwent a 68Ga-PSMA-11 PET/CT or PET/MRI and a BS (CI) (within a maximum time interval of 100 days) were included. Treatment in between both scans was excluded. HVD and LVD was determined on the BS and on the CT or MRI component. CHAARTED stratification into HVD and LVD was also applied to PSMA-PET. HVD was defined by the presence of visceral metastases and / or > 4 bone metastases (with > 1 beyond spine and pelvis). EXINIboneTM 3.4 (EXINI Diagnostics) was used for the number / localization of bone metastases on BS. The whole-body (WB) PSMA-PET positive tumor volume (PSMA-TV) was obtained using a semi-automatic thresholding method on Affinity 3.0.2 (Hermes Medical Solutions).
Results
Paired PSMA-PET+BS of 50 mHSPC patients were included (median PSA 43.8 (0.2 – 2840.0) ng/ml). 13/50 patients had disease detected in the prostate fossa, 25/50 in lymph nodes, 34/50 in bones and 2/50 in visceral organs by CI and 31/50, 28/50, 29/50 and 2/50 by PSMA-PET, respectively. Based on CI, 14/50 patients had CI-HVD (28%) and 36/50 CI-LVD (72%). Based on PSMA-PET, 21/50 patients had PSMA-HVD (42%) and 22/50 PSMA-LVD (44%). 7/50 (14%) patients had no PSMA-positive lesion or only in the prostate fossa while CI was at least CI-LVD. Overall, mean WB-PSMA-TV was 248.1 ml (0 – 3734.0 ml). In CI-HVD, mean WB PSMA-TV was 713.7 (0.3 – 3734.0) ml, in CI-LVD, 46.4 (0-228.0) ml. In PSMA-HVD, 518.1 (0 – 3734.0) ml and in PSMA-LVD, 59.7 (0 – 228.0) ml. Downstaging from CI to PSMA-PET occurred in in 7/50 patients (14.0%), upstaging (LVD to HVD) in 8/50 patients (16.0%).
Conclusions
Stage migration between LVD and HVD from CI to PSMA PET occurs both by up- and downstaging. Correlation with outcome will lead to new definitions of HVD/LVD based on PSMA PET/CT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
W. Fendler: Other, Research Funding: SOFIE Bioscience; Other, Other, Consultant, Speaker: Janssen; Other, Other, Constant, image review: Calyx; Other, Other, Consultant, speaker, research funding: Bayer; Other, Other, Consultant, speaker: Novartis; Other, Other, Speaker: Telix; Other, Other, speaker: GE, Eczacıbaşı Monrol. K. Herrmann: Financial Interests, Personal, Advisory Board: Bayer, Adacap/Novartis, Curium, Boston Scientific, GE Healthcare, AstraZeneca; Financial Interests, Personal, Invited Speaker: Sirtex, Siemens Healthineers, Monrol; Financial Interests, Personal, Other, Consultant: Amgen; Financial Interests, Personal, Other, DMSB: ymabs; Financial Interests, Personal, Advisory Board, Scientific Advisor: AdvanceCell; Financial Interests, Personal, Advisory Board, Advisor, Consultant: Janssen; Financial Interests, Personal, Advisory Board, Consultant: Eco1R; Financial Interests, Personal, Member of Board of Directors: Sofie Biosciences, Theragnostics, Pharma 15; Financial Interests, Personal, Ownership Interest: Sofie Biosciences; Financial Interests, Personal, Stocks/Shares: Aktis Oncology; Non-Financial Interests, Leadership Role, Chair Oncology&Theragnostics Committee: EANM. All other authors have declared no conflicts of interest.
Resources from the same session
1229P - Selective phenotypic and genotypic evaluation of circulating glial cells for improved diagnosis of glial malignancies
Presenter: Sewanti Limaye
Session: Poster session 14
1230P - hPG80 (circulating progastrin) is a new blood-based biomarker for diagnosis of early-stage non-small cell lung cancers
Presenter: Paul Hofman
Session: Poster session 14
1231P - Machine learning prediction of the case-fatality of COVID-19 and risk factors for adverse outcomes in patients with non-small cell lung cancer
Presenter: Yeji Jung
Session: Poster session 14
1232P - Analytic analysis of PanSeer7, a targeted bisulfite sequencing assay for blood-based multi-cancer detection for cancer early detection and tissue-of-origin identification
Presenter: Xinrong Yang
Session: Poster session 14
1233P - Accurate prediction of gastrointestinal cancer tissue of origin using comprehensive plasma cell-free DNA fragmentomics features
Presenter: Xinrong Yang
Session: Poster session 14
1234P - HistoMate: Automated preprocessing software for digital histopathology image to enhance deep learning
Presenter: Jinok Lee
Session: Poster session 14
1235P - Enrichment of rare cancers in pragmatic precision cancer medicine trial: Experience from IMPRESS-Norway
Presenter: Aaslaug Helland
Session: Poster session 14
1236P - Feasibility of online symptom monitoring to detect lung cancer relapse in Poland
Presenter: Ewa Pawlowska
Session: Poster session 14
1237P - Design and validation of a custom next-generation sequencing panel in melanoma, glioma and gastrointestinal stromal tumor
Presenter: Xiaoyan Zhou
Session: Poster session 14
1238P - Detecting driver mutations by AmoyDx 11-gene PCR with high concordance with next-generation sequencing in Chinese non-small cell lung cancer patients
Presenter: Dongmei Lin
Session: Poster session 14